Stock analysts at Wedbush assumed coverage on shares of Maze Therapeutics (NASDAQ:MAZE - Get Free Report) in a research report issued on Tuesday,Benzinga reports. The brokerage set an "outperform" rating and a $17.00 price target on the stock. Wedbush's target price suggests a potential upside of 40.26% from the company's current price.
Separately, Guggenheim reissued a "buy" rating and issued a $19.00 price target on shares of Maze Therapeutics in a research note on Wednesday, April 2nd. Four investment analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company. According to MarketBeat, the company currently has an average rating of "Buy" and an average target price of $23.50.
Check Out Our Latest Stock Analysis on MAZE
Maze Therapeutics Trading Up 5.4%
Shares of Maze Therapeutics stock opened at $12.12 on Tuesday. The stock's 50 day moving average is $11.22. Maze Therapeutics has a one year low of $6.71 and a one year high of $17.00.
Maze Therapeutics (NASDAQ:MAZE - Get Free Report) last posted its quarterly earnings results on Wednesday, May 14th. The company reported ($1.15) EPS for the quarter, missing the consensus estimate of ($0.76) by ($0.39).
Institutional Inflows and Outflows
A number of large investors have recently bought and sold shares of MAZE. General Catalyst Group Management LLC acquired a new stake in shares of Maze Therapeutics during the first quarter valued at about $11,405,000. Bessemer Group Inc. acquired a new stake in shares of Maze Therapeutics during the first quarter valued at about $5,305,000. Hhlr Advisors LTD. acquired a new stake in shares of Maze Therapeutics during the first quarter valued at about $5,037,000. Driehaus Capital Management LLC acquired a new stake in shares of Maze Therapeutics during the first quarter valued at about $1,455,000. Finally, Ghisallo Capital Management LLC acquired a new stake in shares of Maze Therapeutics during the first quarter valued at about $330,000.
Maze Therapeutics Company Profile
(
Get Free Report)
We are a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel, small molecule precision medicines for patients living with renal, cardiovascular and related metabolic diseases, including obesity. We are advancing a pipeline using our Compass platform, which allows us to identify and characterize genetic variants in disease and then link those variants to the biological pathways that drive disease in specific patient groups through a process we refer to as variant functionalization.
See Also
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Maze Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Maze Therapeutics wasn't on the list.
While Maze Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
